Cost-effectiveness analysis of adjuvant treatment for resected pancreatic cancer in China based on the ESPAC-4 trial

References

• KamisawaTWoodLDItoiTTakaoriKPancreatic cancerLancet201638810039738526830752
   PubMed Web of Science ®Google Scholar
• Sato-DahlmanMWirthKYamamotoMRole of Gene Therapy in Pancreatic Cancer—A ReviewCancers2018104103
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• GillenSSchusterTMeyer Zum BüschenfeldeCFriessHKleeffJPreoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentagesPLoS Med201074e100026720422030
   PubMed Web of Science ®Google Scholar
• OettleHNeuhausPHochhausAAdjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic CancerJAMA201331014147324104372
   PubMed Web of Science ®Google Scholar
• LiaoW-CChienK-LLinY-LAdjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysisLancet Oncol201314111095110324035532
   PubMed Web of Science ®Google Scholar
• NeoptolemosJESPAC-1: A Europian randomized controlled study of adjuvant chemoradiation and chemotherapy in resectable pancreatic cancerLancet20013581576158511716884
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDFriessHA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerN Engl J Med2004350121200121015028824
   PubMed Web of Science ®Google Scholar
• OettleHNeuhausPHochhausAAdjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trialJAMA2013310141473148124104372
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDSmithCTAdjuvant 5-fluoroura-cil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trialsBr J Cancer2009100224625019127260
   PubMed Web of Science ®Google Scholar
• ValleJWPalmerDJacksonROptimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 studyJ Clin Oncol201432650451224419109
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDBassiCAdjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trialJAMA2010304101073108120823433
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPMooreMJCoxTFEffect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trialJAMA2012308214715622782416
   PubMed Web of Science ®Google Scholar
• UenoHKosugeTMatsuyamaYA randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBr J Cancer2009101690891519690548
   PubMed Web of Science ®Google Scholar
• LiaoWCChienKLLinYLAdjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysisLancet Oncol201314111095110324035532
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPCoxTFBayesian analysis unravels pancreas-cancer adjuvant therapyLancet Oncol201314111034103524035534
   PubMed Web of Science ®Google Scholar
• OettleHPostSNeuhausPAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialJAMA2007297326727717227978
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPPalmerDHGhanehPComparison of adjuvant gemcitabine and capecitabine with gemcitabine mono-therapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trialLancet2017389100731011102428129987
   PubMed Web of Science ®Google Scholar
• CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJ Clin Oncol200927335513551819858379
   PubMed Web of Science ®Google Scholar
• SultanaASmithCTCunninghamDStarlingNNeoptolemosJPGhanehPMeta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancerJ Clin Oncol200725182607261517577041
   PubMed Web of Science ®Google Scholar
• GoldMPanel on cost-effectiveness in health and medicineMed Care199634Suppl 12197199
   Web of Science ®Google Scholar
• CaldwellDDecision Modelling for Health Economic EvaluationBriggsASculpherMClaxtonKInt J Epidemiol2007362476477
   Google Scholar
• Aalabaf-SabaghiMBook review of Decision Modelling For Health Economic EvaluationBriggsASculpherMClaxtonKJ Epidemiol Commun Health2007619839
   Google Scholar
• ChenHDZhouJWenFCost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancerJ Cancer Res Clin Oncol2017143236136827798730
   PubMed Web of Science ®Google Scholar
• ConroyTDesseigneFYchouMFOLFIRINOX versus gemcitabine for metastatic pancreatic cancerN Engl J Med2011364191817182521561347
   PubMed Web of Science ®Google Scholar
• von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med2013369181691170324131140
   PubMed Web of Science ®Google Scholar
• AttardCLBrownSAlloulKMooreMJCost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancerCurr Oncol20142114151
   PubMed Web of Science ®Google Scholar
• UesakaKBokuNFukutomiAAdjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)Lancet20163881004124825727265347
   PubMed Web of Science ®Google Scholar
• ZhouJZhaoRWenFCost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trialsTumori20162016329430027056335
   PubMed Web of Science ®Google Scholar
• MurrayCJEvansDBAcharyaABaltussenRMDevelopment of WHO guidelines on generalized cost-effectiveness analysisHealth Econ20009323525110790702
   PubMed Web of Science ®Google Scholar
• WuBYeMChenHShenJFCosts of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese contextClin Ther201234246847922325735
   PubMed Web of Science ®Google Scholar
• LazzaroCBaroneCCaprioniFAn Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE studyExpert Rev Pharmacoecon Outcomes Res201818443544629641931
   PubMed Web of Science ®Google Scholar
• CoyleDKoYJCoyleKCost-Effectiveness Analysis of Systemic Therapies in Advanced Pancreatic Cancer in the Canadian Health Care SystemValue Health201720458659228408000
   PubMed Web of Science ®Google Scholar
• ZhouJZhaoRWenFCost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST studyMed Oncol201532412125788034
   PubMed Web of Science ®Google Scholar
• LeeSGJeeYGChungHCCost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)Breast Cancer Res Treat2009114358959518437555
   PubMed Web of Science ®Google Scholar
• LiubaoPXiaominWChongqingTCost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamidePharmacoeconomics2009271087388619803541
   PubMed Web of Science ®Google Scholar